Skip to main content
. 2022 Mar 28;27(Suppl 1):S13–S14. doi: 10.1093/oncolo/oyac011

Table 1.

BYLieve patient cohorts and treatment assignments

Cohort Immediate prior therapy Study treatment
A (n = 112) CDK4/6 inhibitor and an aromatase inhibitor Alpelisib 300mg once daily plus fulvestrant 500 mg
B (n = 112) CDK4/6 inhibitor and fulvestrant Alpelisib 300mg once daily plus letrozole 2.5 mg
C (n = 112) Chemotherapy or endocrine therapy Alpelisib 300mg once daily plus fulvestrant 500 mg